Please use this identifier to cite or link to this item:
https://scholarbank.nus.edu.sg/handle/10635/130378
DC Field | Value | |
---|---|---|
dc.title | The use of vigabatrin in infantile spasms in Asian children | |
dc.contributor.author | Tay, S.K.H. | |
dc.contributor.author | Ong, H.T. | |
dc.contributor.author | Low, P.S. | |
dc.date.accessioned | 2016-11-16T11:05:17Z | |
dc.date.available | 2016-11-16T11:05:17Z | |
dc.date.issued | 2001-01 | |
dc.identifier.citation | Tay, S.K.H., Ong, H.T., Low, P.S. (2001-01). The use of vigabatrin in infantile spasms in Asian children. Annals of the Academy of Medicine Singapore 30 (1) : 26-31. ScholarBank@NUS Repository. | |
dc.identifier.issn | 03044602 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/130378 | |
dc.description.abstract | Background: The use of adrenocorticotrophic hormone (ACTH) and prednisolone in the management of infantile spasms has been well established, but is associated with significant morbidity and cannot be used as long-term medication. Since the introduction of vigabatrin, results have been promising with suggestions currently that it should be used as first-line management of infantile spasms. Aim: The aim of this study was to establish the efficacy, tolerability and problems associated with the use of vigabatrin in Asian children with infantile spasms. Materials and Methods: Eighteen local Asian patients with infantile spasms were given vigabatrin, in 8 as first-line monotherapy and in 10 patients as add-on therapy to pre-existing anti-convulsants. Results: Thirty-nine per cent (7/18) showed 100% suppression of seizures at 2 weeks and 50% (9/18) showing complete suppression of seizures at 4 weeks after starting therapy. There was however, a high relapse rate (56%) in complete responders within the first 6 months of therapy. This was probably due to a lower maintenance dose in the patients, as those who relapsed were on an average dose of 59 mg/kg/day at the time of relapse and responded to a stepped up dose of 83 mg/kg/day. Vigabatrin was well tolerated and only 2 patients developed somnolence and irritability. Conclusion: A dose of at least 70 mg/kg/day may be necessary to achieve adequate control and yet avoid the common adverse affects of vigabatrin. | |
dc.source | Scopus | |
dc.subject | Add-on therapy | |
dc.subject | Infantile spasms | |
dc.subject | Monotherapy | |
dc.subject | Retrospective study | |
dc.subject | Vigabatrin | |
dc.type | Article | |
dc.contributor.department | PAEDIATRICS | |
dc.description.sourcetitle | Annals of the Academy of Medicine Singapore | |
dc.description.volume | 30 | |
dc.description.issue | 1 | |
dc.description.page | 26-31 | |
dc.description.coden | AAMSC | |
dc.identifier.isiut | NOT_IN_WOS | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.